Skip to content
Open access · CC-BY via OpenAlex

Improved Physical Performance Parameters in Patients Taking Nicotinamide Mononucleotide (NMN): A Systematic Review of Randomized Control Trials

Jimmy Wen, Burhaan Syed, Solomon Kim, Mouhamad Shehabat, Ubaid Ansari, Daniel Razick, Muzammil Akhtar, David Pai

Cureus · 2024 · ▲ 6 citations

Abstract

Nicotinamide adenine dinucleotide (NAD+) is essential in the proper function of many essential cellular processes in the human body. The purpose of this review is to investigate the effect of nicotinamide mononucleotide (NMN), a NAD+ precursor, on physical performance and evaluate the safety profile of supplementation. A systematic review search criteria following the guidelines from the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) was performed in four databases for randomized controlled trials on NMN supplementation. Study variables included title, author, publication date, study year, number of patients, dosage, mean age, mean follow-up time, pre- and post-intervention reported outcomes, and rates of complications. Ten studies, including 437 patients, with a mean age of 58.0 years (35.1 to 81.1 years) and a mean follow-up time of 9.6 weeks (4 to 12 weeks) were included in this study. NMN dosages ranged from 150 to 1200 mg/day. Mean pre-intervention grip strength (two studies) and skeletal mass index (two studies) were 29.9 kilograms (kg) (range: 21.4-40.1 kg) and 7.4 kg/m2 (range: 6.9-7.65 kg/m2), respectively. Mean post-intervention grip strength and skeletal mass index were 30.5 kg (range: 21.7-41.9 kg) and 7.4 kg/m2 (6.8-7.64 kg/m2), respectively. There were no serious adverse effects observed. Moreover, of the reported side effects, they were determined to be independent of NMN supplementation. Therefore, patients taking NMN supplementation demonstrated non-significantly improved physical performance parameters. NMN is well tolerated with no serious adverse effects observed.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.7759/cureus.65961
Canonical
link ↗
Fetched
2026-10-31 MST

Cite this

APA
Wen, J., Syed, B., Kim, S., Shehabat, M., Ansari, U., Razick, D., Akhtar, M., &amp; Pai, D. (2024). Improved Physical Performance Parameters in Patients Taking Nicotinamide Mononucleotide (NMN): A Systematic Review of Randomized Control Trials. <em>Cureus</em>. https://doi.org/10.7759/cureus.65961
Vancouver
Wen J, Syed B, Kim S, Shehabat M, Ansari U, Razick D, et al. Improved Physical Performance Parameters in Patients Taking Nicotinamide Mononucleotide (NMN): A Systematic Review of Randomized Control Trials. Cureus. 2024. doi:10.7759/cureus.65961.
BibTeX
@article{jimmy2024Improv, title = {Improved Physical Performance Parameters in Patients Taking Nicotinamide Mononucleotide (NMN): A Systematic Review of Randomized Control Trials}, author = {Jimmy Wen and Burhaan Syed and Solomon Kim and Mouhamad Shehabat and Ubaid Ansari and Daniel Razick and Muzammil Akhtar and David Pai}, journal = {Cureus}, year = {2024}, doi = {10.7759/cureus.65961}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings